Nyxoah Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
184
- Stock Symbol
-
NYXH
- Share Price
-
$8.06
- (As of Wednesday Closing)
Nyxoah General Information
Description
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Contact Information
Website
www.nyxoah.comCorporate Office
- Rue Edouard Belin 12
- 1435 Mont-Saint-Guibert
- Belgium
Corporate Office
- Rue Edouard Belin 12
- 1435 Mont-Saint-Guibert
- Belgium
Nyxoah Timeline
Nyxoah Stock Performance
As of 21-May-2025, Nyxoah’s stock price is $8.06. Its current market cap is $302M with 37.4M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.06 | $7.05 | $5.54 - $11.72 | $302M | 37.4M | 82K | -$2.13 |
Nyxoah Financials Summary
As of 31-Mar-2025, Nyxoah has a trailing 12-month revenue of $4.68M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 197,853 | 268,474 | 72,154 | 40,232 |
| Revenue | 4,685 | 4,892 | 4,705 | 3,243 |
| EBITDA | (59,847) | (48,316) | (29,712) | |
| Net Income | (74,839) | (64,099) | (46,759) | (32,830) |
| Total Assets | 147,092 | 164,833 | 137,243 | 156,646 |
| Total Debt | 23,908 | 23,572 | 14,043 | 12,743 |
Nyxoah Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nyxoah Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Nyxoah Comparisons
Industry
Financing
Details
Nyxoah Competitors (7)
One of Nyxoah’s 7 competitors is Inspire Medical Systems, a Formerly VC-backed company based in Golden Valley, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inspire Medical Systems | Formerly VC-backed | Golden Valley, MN | ||||
| Cryosa | Venture Capital-Backed | Arden Hills, MN | ||||
| ResMed | Corporation | San Diego, CA | ||||
| Somnics | Venture Capital-Backed | Zhubei, Taiwan | ||||
| Wellell | Venture Capital-Backed | New Taipei, Taiwan |
Nyxoah Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nyxoah Patents
Nyxoah Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4241675-A1 | Method and system for sensing a subject's breathing and use of the method and system in treating obstructive sleep apnea | Pending | 11-Mar-2022 | ||
| EP-4241674-A1 | Method and system for measuring a degree of muscle displacement and use of the method and system in treating obstructive sleep apnea | Pending | 11-Mar-2022 | ||
| AU-2023232297-A1 | Method and system for measuring a degree of muscle displacement and use of the method and system in treating obstructive sleep apnea | Pending | 11-Mar-2022 | ||
| AU-2023229896-A1 | Method and system for sensing a subject's breathing and use of the method and system in treating obstructive sleep apnea | Pending | 11-Mar-2022 | ||
| EP-4119038-A1 | Method for quantification of a level of response to hypoglossal nerve stimulation | Pending | 12-Jul-2021 | A61B5/4818 |
Nyxoah Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nyxoah Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nyxoah ESG
Risk Overview
Risk Rating
Updated December, 21, 2023
30.24 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,048
Rank
Percentile
Healthcare
Industry
of 635
Rank
Percentile
Medical Devices
Subindustry
of 225
Rank
Percentile
Nyxoah FAQs
-
When was Nyxoah founded?
Nyxoah was founded in 2009.
-
Where is Nyxoah headquartered?
Nyxoah is headquartered in Mont-Saint-Guibert, Belgium.
-
What is the size of Nyxoah?
Nyxoah has 184 total employees.
-
What industry is Nyxoah in?
Nyxoah’s primary industry is Therapeutic Devices.
-
Is Nyxoah a private or public company?
Nyxoah is a Public company.
-
What is Nyxoah’s stock symbol?
The ticker symbol for Nyxoah is NYXH.
-
What is the current stock price of Nyxoah?
As of 21-May-2025 the stock price of Nyxoah is $8.06.
-
What is the current market cap of Nyxoah?
The current market capitalization of Nyxoah is $302M.
-
What is Nyxoah’s current revenue?
The trailing twelve month revenue for Nyxoah is $4.68M.
-
Who are Nyxoah’s competitors?
Inspire Medical Systems, Cryosa, ResMed, Somnics, and Wellell are some of the 7 competitors of Nyxoah.
-
What is Nyxoah’s annual earnings per share (EPS)?
Nyxoah’s EPS for 12 months was -$2.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
